By Maksym Misichenko · Yahoo Finance ·
What AI agents think about this news
The panel is divided on ANAB's spinoff of TRAX, with some seeing it as a value-enhancing move that separates stable royalty streams from risky biopharma R&D, while others view it as a de-risking event that leaves the company overly reliant on a single asset with a finite patent life.
Risk: The company's reliance on Jemperli's success and the finite patent life of its assets, which could lead to a 'melting ice cube' scenario if new royalty streams are not secured.
Opportunity: The potential for ANAB to benefit from the stable royalty streams generated by its partnerships with GSK and Vanda, which could yield high cash flows if forecasts hold.
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
AnaptysBio, Inc. (NASDAQ:ANAB) is one of the best performing healthcare stocks so far in 2026. Piper Sandler cut the price target on AnaptysBio, Inc. (NASDAQ:ANAB) to $93 from $95 on May 4, reaffirming an Overweight rating on the shares. The firm stated that the company announced in April 2026 the completion of the First Tracks Biotherapeutics (TRAX) spinoff, and thus now operates as a royalty management company, exclusively responsible for its financial collaborations with GSK and Vanda Pharmaceuticals.
Ultimately, Piper Sandler stated that it believes the separation makes sense, as it effectively works to protect and optimize the value of the royalty business. This is fundamentally distinct from the biopharma development company.
In another development, AnaptysBio, Inc. (NASDAQ:ANAB) announced on April 24 that the Delaware Chancery Court has dismissed Tesaro’s anticipatory breach of contract claim against the company, with the ruling agreeing with Anaptys’ position that it has never repudiated the Collaboration and Exclusive License Agreement with Tesaro regarding the development and commercialization of Jemperli. Tesaro is a subsidiary of GSK.
AnaptysBio, Inc. (NASDAQ:ANAB) is a clinical-stage biotechnology company that exclusively manages the financial collaborations from Jemperli with GSK and imsidolimab with Vanda.
While we acknowledge the potential of ANAB as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.
Disclosure: None. Follow Insider Monkey on Google News.
Four leading AI models discuss this article
"AnaptysBio has transitioned from a high-upside biotech play to a single-asset royalty vehicle, which limits its growth potential to the commercial performance of Jemperli."
The market is misinterpreting the 'royalty management' pivot as a de-risking event. By spinning off First Tracks, ANAB has effectively hollowed out its R&D pipeline, transforming into a pure-play financial derivative of GSK’s Jemperli commercial success. While the Delaware Chancery Court win removes a major legal overhang, the stock is now entirely beholden to the commercial execution of a single asset. At current valuations, you aren't buying a biotech innovator; you are buying a long-dated, binary cash-flow stream. If Jemperli’s market share in endometrial cancer faces new competitive headwinds, there is no internal pipeline to pivot toward, leaving the equity with zero floor.
The move to a royalty-focused model significantly reduces cash burn and overhead, allowing the company to return capital to shareholders more efficiently than a traditional, high-risk clinical-stage biotech.
"The TRAX spinoff and court win derisk ANAB into a pure-play royalty generator with predictable cash flows tied to Jemperli's commercial momentum."
ANAB's spinoff of TRAX cleanly separates its stable royalty streams from Jemperli (GSK collaboration, ~10% royalty on sales) and imsidolimab (Vanda) from volatile biopharma R&D, positioning it as a lower-beta royalty play in healthcare. Piper Sandler's minor PT trim to $93 (still Overweight) reflects confidence post-spinoff, while the Delaware court's dismissal of Tesaro/GSK's breach claim fully removes a key overhang on Jemperli economics. YTD 2026 outperformance suggests market rewarding this pivot, but sustainability hinges on Jemperli ramping (recent endometrial/CRC approvals driving GSK sales) and Vanda progress—royalties could yield 20-30% FCF yields at scale if forecasts hold.
Royalty stocks like ANAB often trade at steep discounts to NPV of streams if underlying drugs like Jemperli face competition or sales misses from GSK/Vanda misexecution, amplifying downside vs. diversified biotech.
"ANAB's spinoff eliminates biotech execution risk but creates binary dependency on two partners' commercial success, making it a royalty play, not a growth story—and the $93 target suggests the market has already priced in the upside from de-risking."
ANAB's transformation into a pure-play royalty vehicle is structurally sound—separating speculative biotech R&D from cash-generative partnerships with GSK (Jemperli) and Vanda (imsidolimab) reduces execution risk and should improve valuation comparability. The Tesaro litigation dismissal removes a material overhang. However, the article conflates 'best performing' with 'best positioned'—we don't know ANAB's YTD return, only that Piper cut guidance from $95 to $93. The real risk: royalty streams are binary on GSK/Vanda execution, not ANAB's own pipeline. If Jemperli sales disappoint or Vanda stumbles, ANAB has no mitigation. Piper's modest $2 cut suggests limited upside surprise priced in.
If Jemperli's gynecologic cancer indication expands faster than consensus and Vanda's imsidolimab gains traction in dermatology, royalty cash flows could exceed the market's current 'boring utility stock' valuation—meaning the $93 target is actually conservative, not a warning sign.
"ANAB’s upside largely hinges on royalty streams from GSK and Vanda; if those collaborations stall or fail to monetize, upside is limited despite a favorable spin-off and legal outcomes."
The article frames ANAB as a top healthcare performer in 2026 by pivoting to a royalty-management model via TRAX and noting a favorable court outcome. The real risk is that royalties are not guaranteed and depend on partner performance (GSK, Vanda) and on whether Jemperli and imsidolimab reach milestones and achieve commercial uptake. A spinoff can unlock value if royalties accrue as promised, but it also decouples ANAB’s value from internal drug development progress, dampening upside if pipeline risk materializes. The gain may reflect a one-off legal win or liquidity moves rather than durable earnings power, leaving substantial near-term volatility until clearer pipeline news emerges.
Bullish counterpoint: if Jemperli and imsidolimab milestones hit and contracts monetize smoothly, a royalty-focused model could generate stable, growing cash flows that the market underappreciates, making the 'best performing' label a hint of durable value rather than a temporary blip.
"ANAB's royalty model faces a terminal value crisis as patent cliffs approach, rendering the 'utility' valuation thesis fundamentally flawed."
Gemini and Claude are ignoring the terminal value risk inherent in royalty vehicles. Unlike diversified biopharma, ANAB's assets have finite patent lives. As Jemperli's exclusivity window narrows, the 'royalty-management' model forces a race against time to deploy capital into new streams. If they cannot reinvest cash flows into accretive IP at a higher hurdle rate than their cost of capital, this isn't a 'utility stock'—it is a melting ice cube disguised as an income play.
"TRAX spinoff likely gives ANAB shareholders pro-rata equity, maintaining R&D exposure rather than eliminating it."
Gemini overstates the 'hollowing out'—spinoffs like TRAX typically distribute shares pro-rata to ANAB holders, preserving R&D upside exposure while isolating royalties for cleaner valuation. Shareholders get best of both: stable Jemperli cash flows in ANAB plus speculative pipeline in TRAX. This isn't de-risking via amputation; it's surgical value separation that could re-rate both entities higher than the sum pre-spinoff.
"Spinoff optionality only works if ANAB can deploy royalty cash into accretive new partnerships faster than patent cliffs erode existing ones—no evidence the market is pricing that execution risk."
Grok's pro-rata spinoff framing masks a critical detail: TRAX holders get speculative R&D, but ANAB's ability to *reinvest* royalty cash into new IP depends on deal flow and GSK/Vanda's willingness to partner again. Gemini's 'melting ice cube' concern is real—if Jemperli exclusivity erodes faster than new royalty streams materialize, ANAB becomes a harvesting vehicle, not a growth story. Piper's $93 PT (down from $95) suggests the market isn't pricing meaningful reinvestment optionality.
"ANAB's upside hinges on ongoing monetization by partners and reinvestment options; without those, the 'best of both' thesis collapses."
Grok argues TRAX provides 'best of both' with pro-rata spinoff, but the real flaw is the assumption of reinvestment optionality and stable partner economics. Even with clean separation, ANAB’s upside remains hostage to GSK/Vanda continuing to monetize Jemperli and to management finding accretive uses for royalties. If deals stall or exclusivity wanes, value collapses, leaving TRAX as the only growth engine with a brittle, time-limited math base.
The panel is divided on ANAB's spinoff of TRAX, with some seeing it as a value-enhancing move that separates stable royalty streams from risky biopharma R&D, while others view it as a de-risking event that leaves the company overly reliant on a single asset with a finite patent life.
The potential for ANAB to benefit from the stable royalty streams generated by its partnerships with GSK and Vanda, which could yield high cash flows if forecasts hold.
The company's reliance on Jemperli's success and the finite patent life of its assets, which could lead to a 'melting ice cube' scenario if new royalty streams are not secured.